Form 4 for NVCT Nuvectis Pharma, Inc.
Accepted 2022-04-05 00:00:00 ET · period of report 2022-04-01 · accession 0001104659-22-042814 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-05 | 2022-04-01 | NVCT | Shemesh Shay | Chief Dev, Ops. Off | A - Grant | $0.00 | +60.0K | 1.24M | +5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-04-01 | A | A | 60,000 | $0.00 | 1,239,615 | D | — | — | (F1) The restricted stock units will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025. (F2) Includes 48,399 shares of restricted stock and 60,000 restricted stock units. |